No headlines found.
Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer
Globe Newswire (Wed, 24-Apr 4:30 PM ET)
Globe Newswire (Thu, 11-Apr 7:00 AM ET)
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
Globe Newswire (Mon, 18-Mar 4:40 PM ET)
Arvinas to Participate in Upcoming Investor Conferences
Globe Newswire (Mon, 4-Mar 7:00 AM ET)
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Globe Newswire (Tue, 27-Feb 7:00 AM ET)
Arvinas Announces Chief Financial Officer Transition
Globe Newswire (Tue, 20-Feb 4:05 PM ET)
Globe Newswire (Tue, 20-Feb 7:00 AM ET)
Globe Newswire (Wed, 14-Feb 8:00 AM ET)
Globe Newswire (Tue, 6-Feb 6:45 AM ET)
Arvinas to Present at 6th Annual Guggenheim Biotechnology Conference
Globe Newswire (Thu, 1-Feb 4:30 PM ET)
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.
Arvinas trades on the NASDAQ stock market under the symbol ARVN.
As of April 26, 2024, ARVN stock price climbed to $32.09 with 569,984 million shares trading.
ARVN has a beta of 2.40, meaning it tends to be more sensitive to market movements. ARVN has a correlation of 0.14 to the broad based SPY ETF.
ARVN has a market cap of $2.19 billion. This is considered a Mid Cap stock.
Last quarter Arvinas reported $-43 million in Revenue and -$2.53 earnings per share. This fell short of revenue expectation by $-92 million and missed earnings estimates by -$1.25.
In the last 3 years, ARVN stock traded as high as $108.47 and as low as $13.57.
The top ETF exchange traded funds that ARVN belongs to (by Net Assets): VTI, VB, VXF, IWM, VBK.
ARVN has underperformed the market in the last year with a price return of +18.8% while the SPY ETF gained +26.9%. ARVN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -15.0% and -13.9%, respectively, while the SPY returned +4.5% and -1.8%, respectively.
ARVN support price is $30.57 and resistance is $32.63 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARVN stock will trade within this expected range on the day.